CheckMate 227 trial: Nivolumab + ipilimumab shows remarkable six-year survival benefits in metastatic NSCLC

Reviewed by Lily Ramsey, LLMSep 11 2023 Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.

Our findings represent a pivotal moment in the management of metastatic NSCLC. The extended survival and enhanced quality of life observed with nivolumab + ipilimumab underscores the potential for a paradigm shift in treatment strategies." The study enrolled adults with treatment- naïve stage IV or recurrent NSCLC, excluding those with known EGFR/ALK alterations and with ECOG performance status of ≤1.

Related StoriesAdditional endpoints, including objective response rates, duration of response, and quality of life, consistently favored the nivolumab + ipilimumab combination across all patient subgroups. Notably, responders with substantial tumor burden reduction exhibited considerably improved overall survival with nivolumab + ipilimumab compared to chemotherapy.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Durvalumab shows tolerable surgical safety profile in patients with resectable NSCLCAdding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
Source: NewsMedical - 🏆 19. / 71 Read more »